

Drug Monograph

[Drug Name](#) | [Mechanism of Action and Pharmacokinetics](#) | [Indications and Status](#) | [Adverse Effects](#) | [Dosing](#) | [Administration Guidelines](#) | [Special Precautions](#) | [Interactions](#) | [Recommended Clinical Monitoring](#) | [Supplementary Public Funding](#) | [References](#) | [Disclaimer](#)

A - Drug Name**aXitinib**

COMMON TRADE NAME(S): Inlyta®

[back to top](#)

B - Mechanism of Action and Pharmacokinetics

Axitinib is an inhibitor of VEGF receptor tyrosine kinases 1, 2, and 3. These receptors are involved with pathologic angiogenesis, growth and metastases of cancer cells.

Absorption	Pharmacokinetics is dose proportional and linear. Daily dosing results in an approximately 1.4-fold accumulation compared with administration of a single dose.	
	Bioavailability	58%
	Time to reach steady state	2 to 3 days
Distribution	PPB	> 99%; mainly to albumin and moderate binding to alpha 1-acid glycoprotein
Metabolism	Metabolized mainly in the liver. Sulfoxide and N-glucuronide metabolites have been demonstrated to be ~ 400-fold and 8000-fold less potent <i>in vitro</i> respectively against VEGFR-2 compared with axitinib.	
Elimination	Urine	23% (primarily carboxylic acid and sulfoxide metabolites)
	Feces	41% (12% unchanged)

Half-life	2.5 - 6.1 hours
-----------	-----------------

[back to top](#)

C - Indications and Status

Health Canada Approvals:

- Renal cell carcinoma

Refer to the product monograph for a full list and details of approved indications.

[back to top](#)

D - Adverse Effects

Emetogenic Potential: Minimal – No routine prophylaxis; PRN recommended

ORGAN SITE	SIDE EFFECT* (%)	ONSET**
Auditory	Tinnitus (3%)	E
Cardiovascular	Arterial thromboembolism (1%) (including retinal)	E
	Artery aneurysm (rare)	E D L
	Artery dissection (rare)	E D L
	Bradycardia	E
	Cardiotoxicity (2%) (may be severe)	D
	Hypertension (40%) (1% grade 4)	E
	Venous thromboembolism (3%)	E
Dermatological	Alopecia (4%)	E
	Hand-foot syndrome (27%) (severe 5%)	E
	Rash (13%)	E
Gastrointestinal	Abdominal pain (14%)	E
	Anorexia, weight loss (34%)	E
	Constipation (20%)	E

	Diarrhea (55%)	E
	Dyspepsia (10%)	E
	GI perforation (1%) (or fistula)	E
	Mucositis (15%)	E
	Nausea, vomiting (32%)	I
General	Fatigue (39%)	E
Hematological	Hemoglobin increased (10%)	E
	Hemorrhage (16%) (may be severe)	E
	Myelosuppression ± infection (15%) (may be severe)	E
Hepatobiliary	↑ Amylase / lipase (27%)	E
	↑ LFTs (22%)	E
Metabolic / Endocrine	Abnormal electrolyte(s) (17%)	E
	Hyperglycemia (28%)	E
	Hyperthyroidism (1%)	E D
	Hypoglycemia (11%)	E
	Hypothyroidism (19%)	E
Musculoskeletal	Musculoskeletal pain (15%)	E
Nervous System	Dizziness (9%)	E
	Dysgeusia (11%)	E
	Headache (14%)	E
	Posterior reversible encephalopathy syndrome (PRES) (<1%)	E
Renal	Creatinine increased (55%) (2% severe)	E
	Proteinuria (11%)	E
Respiratory	Cough, dyspnea (15%)	E
	Hoarseness (31%)	E

* "*Incidence*" may refer to an absolute value or the higher value from a reported range.
 "*Rare*" may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies, isolated data or anecdotal reports.

** I = *immediate* (onset in hours to days) E = *early* (days to weeks)
 D = *delayed* (weeks to months) L = *late* (months to years)

The most common side effects for axitinib include diarrhea, hypertension, fatigue, anorexia, weight loss, lymphopenia, nausea and vomiting.

Hypertension is common and may be severe. It must be controlled prior to starting treatment and monitored carefully with axitinib dose modifications. (Refer to [Management of Angiogenesis Inhibitor \(AI\)-Induced Hypertension](#).) Cardiac effects are more common than with sunitinib and may be fatal.

Reversible Posterior Leukoencephalopathy Syndrome may present with headache, seizure, lethargy, confusion, blindness and potentially other visual and neurologic disturbances. It may also be associated with mild to severe hypertension.

Severe cases of **artery dissection** (with or without hypertension) and **artery aneurysm** (including rupture) have been reported in patients using VEGFR TKIs.

Hemorrhages occurred during the pivotal trial. These hemorrhagic events included cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage and melena. Axitinib should be used with caution in patients with significant risk for bleeding events. For patients with untreated brain metastases, history of pulmonary embolism in previous 6 months, or with a history of active bleeding in the previous 3 months, it is not recommended to administer axitinib.

Gastrointestinal perforation, including death and gastrointestinal fistulas have been reported.

Arterial and venous thromboembolisms have been reported. Clinical trials excluded patients who had recent arterial (within 1 year) and venous (within 6 months) thromboses.

Thyroid dysfunction has been reported in the pivotal trial. Events involving both hypothyroidism and hyperthyroidism have occurred.

Hand-foot syndrome may be severe and present with redness and pain on the palms of the hands and soles of the feet. It may occur on other areas of the body surface. Prevention of hand-foot syndrome includes control of calluses and minimizing pressure stress to soles and palms. Consider initiating treatment with topical therapies as soon as symptoms occur. Management may include the use of keratolytic creams (e.g. urea, salicylic acid, or alpha hydroxyl acid-based creams applied sparingly only on hyperkeratotic areas) and moisturizing creams (applied liberally) for symptomatic relief.

[back to top](#)

E - Dosing

Refer to protocol by which patient is being treated.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the [hepatitis B virus screening and management](#) guideline.

Do not start treatment until any hypertension is controlled and platelets are $\geq 100 \times 10^9/L$ and ANC $\geq 1.5 \times 10^9/L$.

Correct electrolyte abnormalities prior to treatment, especially potassium, calcium and magnesium.

Hold axitinib for at least 24 hours prior to planned surgery. Re-start post-surgery based on clinical assessment of wound healing.

Adults:

Oral: 5 mg twice daily; may be titrated up to a maximum of 10 mg twice daily according to tolerance

Dosage with Toxicity:

Dose Level	Dose
+2	10 mg BID
+1	7 mg BID*
0 (starting dose)	5 mg BID*
-1	3 mg BID
-2	2 mg BID

*May \uparrow 1 dose level in patients who tolerate (\leq grade 2 toxicity) the current dose for 2 consecutive weeks, with no prior dose modification, normotensive and do not require antihypertensive medications

Do not re-escalate a dose reduced for toxicity.

Toxicity	Action
Grade 3 related organ / non-hematologic	Hold*; ↓ 1 dose level
Moderate or severe proteinuria	↓ 1 dose level Consider temporary discontinuation of therapy in severe proteinuria*
Hypertension	Treat appropriately (refer to Management of Angiogenesis Inhibitor (AI)-Induced Hypertension). Reduce dose or hold as appropriate.
Grade 4 related organ/ non-hematologic; uncontrolled hypertension/crisis; RPLS; heart failure; wound dehiscence	Discontinue

*Do not start new cycle until toxicities have recovered to ≤ grade 2, platelets ≥ 100 x 10⁹/L, and ANC ≥ 1.5 x 10⁹/L.

Dose Modification for Hepatotoxicity in Combination with Pembrolizumab

ALT or AST		Bilirubin	Action
≥ 3 to < 10 x ULN	And	< 2 X ULN	Hold pembrolizumab and axitinib until ≤ grade 1. Consider corticosteroids. After recovery, consider re-challenge with a single drug or sequentially with both drugs. Consider dose reduction if rechallenging with axitinib.
> 3 x ULN	And	≥ 2 x ULN	Discontinue both drugs.
≥ 10 x ULN	And	Any	Consider corticosteroids.

Dosage with Hepatic Impairment:

Axitinib exposure is increased in moderate hepatic impairment, but has not been studied in patients with severe impairment.

Hepatic impairment	Starting dose
Mild hepatic impairment (Child-Pugh class A)	No dose adjustment required
Moderate hepatic impairment (Child-Pugh class B)	↓ dose by approximately 50%
Severe hepatic impairment (Child-Pugh class C)	Do not use (no data)

Higher than expected incidences of severe LFT elevations have been reported in axitinib in combination with pembrolizumab.

Dosage with Renal Impairment:

Creatinine Clearance (mL/min)	Dose
15 - 89	No dosage adjustments required.
< 15	Use with caution.

Dosage in the elderly:

No dosage adjustments required.

Children:

Axitinib should not be administered to children under 18 years of age. Safety and effectiveness in pediatric patients have not been established. Angiogenesis inhibitors are expected to result in a number of issues in pediatric patients including physal dysplasia.

[back to top](#)

F - Administration Guidelines

- Tablets should be swallowed whole with a glass of water, with or without food.
- Grapefruit, starfruit, Seville oranges, their juices or products should be avoided during treatment.
- If a dose is missed, patient should skip the missed dose and take the next dose at the next scheduled time.
- Store at room temperature (25°C). Excursions permitted to 15-30°C.

[back to top](#)

G - Special Precautions

Contraindications:

- Patients who have a hypersensitivity to this drug or any of its components

Other Warnings/Precautions:

- Use with caution in patients at risk of or who have a history of arterial or venous thromboembolism.
- Use with caution in patients at risk of bleeding. Axitinib is not recommended for use in patients with untreated brain metastases, a history of pulmonary embolism in the past 6 months, or active bleeding in the past 3 months.
- Use axitinib with caution in bradycardic patients or patients at risk of bradyarrhythmia.
- Clinical trials excluded patients with uncontrolled hypertension at baseline or a recent history of MI, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident, TIA, deep vein thrombosis or pulmonary embolism.
- Tablets contain lactose; carefully consider use in patients with hereditary galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.

Other Drug Properties:

- Carcinogenicity: Unknown

Pregnancy and Lactation:

- Embryotoxicity: Yes
 - Fetotoxicity: Yes
 - Teratogenicity: Yes
 - Mutagenicity: No
 - Genotoxicity: Yes
 - Clastogenicity: No
- Axitinib should not be used in pregnancy. Adequate contraception should be used by both sexes during treatment, and for at least **1 week** after the last dose.
- Excretion into breast milk: Unknown
Breastfeeding is not recommended.
 - Fertility effects: Probable

[back to top](#)

H - Interactions

Axitinib is metabolized primarily by CYP3A4/5. It is metabolized to a lesser extent by CYP 1A2, CYP2C19 and UGT1A1.

Axitinib is not expected to inhibit the metabolism drugs that are substrates of CYP2A6, 2C9, 2C19, 2D6, 2E1, 3A4/5, UGT1A1 or P-glycoprotein, nor induce CYP1A1, 1A2 or CYP3A4/5.

AGENT	EFFECT	MECHANISM	MANAGEMENT
CYP3A4/5 inhibitors (i.e. ketoconazole, clarithromycin, ritonavir, fruit or juice from grapefruit, Seville oranges, starfruit, etc.)	↑ axitinib exposure and/or toxicity	↓ metabolism of axitinib	Avoid strong inhibitors if possible; axitinib dose reduction recommended if co-administration with potent inhibitors is necessary
CYP3A4/5 inducers (i.e. phenytoin, rifampin, dexamethasone, carbamazepine, phenobarbital, St. John's Wort, etc)	↓ axitinib concentration and/or efficacy	↑ metabolism of axitinib	Avoid strong inducers and, if possible, moderate inducers

Drugs that increase gastric pH (e.g. antacids, PPI, H2 antagonists)	↓ axitinib exposure	↓ exposure with increased pH	Caution; avoid these agents 2 hours before to 2 hours after axitinib is administered
CYP1A2 substrates (e.g. theophylline) and CYP2C8 substrates (e.g. paclitaxel, sorafenib)	Potentially ↑ substrate exposure	Axitinib has potential to inhibit CYP1A2 and CYP2C8	Caution; monitor for drugs with narrow therapeutic range

[back to top](#)

I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Refer to the [hepatitis B virus screening and management](#) guideline for monitoring during and after treatment.

Recommended Clinical Monitoring

Monitor Type	Monitor Frequency
CBC	Baseline and at each visit
Blood pressure	Baseline and at each visit; start within a week after beginning treatment, more frequent after dose changes or interruptions
Liver function tests (ALT, AST and bilirubin)	Baseline and at each visit (consider more frequent monitoring when used in combination with pembrolizumab)
Renal function tests	Baseline and at each visit
Thyroid function tests	Baseline and as clinically indicated
Proteinuria	Baseline and as clinically indicated
Signs and symptoms of cardiotoxicity	Baseline and periodically during treatment
Clinical toxicity assessment for bleeding,	At each visit

thromboembolism, neurological and GI effects	
--	--

Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

[back to top](#)

J - Supplementary Public Funding

Exceptional Access Program ([EAP Website](#))

- aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria
- aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

[back to top](#)

K - References

Fischer A, Wu SH, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. *Invest New Drugs* 2013;31:787-97.

Prescribing Information: Inlyta[®] (axitinib). Pfizer Labs (U.S.), September 2022.

Product Monograph: Inlyta[®] (axitinib). Pfizer Product ULC, September 2021.

Product Monograph: Stivarga[®] (regorafenib). Bayer Inc., October 2, 2013.

Rini BI, Plimack ER, Stus V, et al. KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019;380(12):1116-27.

Rini BI et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet* 2011;378:1931-9.

Rini BI et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. *J Clin Oncol* 2009;27(27): 4462-8.

van Leeuwen RW, van Gelder T, Mathijssen RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. *Lancet Oncol.* 2014;15(8):e315-e326.

February 2023 Updated Pharmacokinetics, Dose modifications (with pembrolizumab), Dosage in hepatic impairment, Special Precautions, Pregnancy and Monitoring sections.

[back to top](#)

L - Disclaimer

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)